🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Institut de Recherches Internationales Servier clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and Ireland registers with Institut de Recherches Internationales Servier as lead sponsor. Synced 26 Sep 2026
4Current trials
1Recruiting now
11Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Institut de Recherches Internationales Servier is the lead sponsor of 4 current clinical trials in our China and Ireland registers. 1 is recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are AG-120, Azacitidine and Capecitabine. The most-studied condition is Metastatic Colorectal Cancer.

ClinicalTrials.gov trials by status

  • Recruiting125%
  • Active, closed375%

Trials by phase

  • Phase 3250%
  • Phase 1/2250%
01

Clinical trials sponsored by Institut de Recherches Internationales Servier

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis
Phase 1/2 Recruiting 2023-04 China
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892 · Metastatic Colorectal Cancer
Phase 3 Active, closed 2019-03 Ireland
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)
Phase 3 Active, closed 2017-06 China
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT06478212 · ClinicalTrials.gov ↗ · IDH1-mutant Glioma, IDH2-mutant Glioma
Phase 1/2 Active, closed 2025-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Institut de Recherches Internationales Servier trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Institut de Recherches Internationales Servier trials

11 conditions
Metastatic Colorectal Cancer1Non-small Cell Lung Cancer1Histiocytic Neoplasm1Histiocytosis1BRAF Gene Mutation1Newly Diagnosed Acute Myeloid Leukemia (AML)1Untreated AML1AML Arising From Myelodysplastic Syndrome (MDS)1Leukemia, Myeloid, Acute1IDH1-mutant Glioma1IDH2-mutant Glioma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China31
Clinical trials in Ireland10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Metastatic Colorectal Cancer

SponsorTrials
Liu Huang2
The First Hospital of Jilin University2
Riboscience1
Shanghai EpimAb Biotherapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about Institut de Recherches Internationales Servier trials

How many clinical trials does Institut de Recherches Internationales Servier sponsor?

Institut de Recherches Internationales Servier is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Institut de Recherches Internationales Servier trials recruiting?

Yes. 1 of its 4 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Institut de Recherches Internationales Servier testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are AG-120 (1), Azacitidine (1), Capecitabine (1), Cetuximab (1) and Folfiri (1). The number in brackets is how many of its trials name each drug.

Does Institut de Recherches Internationales Servier have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.